ofloxacin has been researched along with Leukemia in 18 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin reduced the bacterial infections and delays the onset of fever in chemotherapy-induced neutropenia especially in short duration (< 7 days)." | 6.74 | Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. ( Khan, MA; Rahman, MM, 2009) |
| "We performed population pharmacokinetic analysis for seven patients receiving LVFX as prophylaxis (200 mg, b." | 6.73 | Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ( Fujimoto, Y; Kanbayashi, Y; Matsumoto, Y; Morimoto, Y; Nomura, K; Taniwaki, M, 2008) |
| "These findings suggest that, despite increasing rates of antimicrobial resistance, levofloxacin prophylaxis during neutropenia may have a beneficial impact on morbidity and infection-related mortality." | 5.11 | Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. ( Döhner, H; Kern, P; Kern, WV; Marre, R; Reuter, S; Sigge, A; von Baum, H, 2005) |
| " In a prospective, randomized, open trial, we evaluated the efficacy and safety of oral roxithromycin (150 mg twice daily) as additional antibacterial prophylaxis in 131 adult patients with acute leukemia and bone marrow transplant recipients receiving oral ofloxacin." | 5.07 | A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. ( Arnold, R; Hay, B; Kern, P; Kern, WV; Marre, R, 1994) |
| "We evaluated the effectiveness of ofloxacin (OFX) administered for prophylactic purposes during 77 episodes of neutropenia (less than 500/mm3) in 54 patients with hematological malignancies and to combat infection in 17 patients with both hematological malignancies and secondary infections." | 5.07 | Use of ofloxacin in prevention and treatment of secondary infections in hematological malignancies. ( Okuma, M; Sawada, H; Tashima, M, 1991) |
| "The efficacy and safety of oral ofloxacin were compared with those of vancomycin/polymyxin for prophylaxis of bacterial infections in granulocytopenic patients undergoing chemotherapy for hematologic malignancy." | 5.06 | Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. ( Bruckner, DA; Champlin, RE; Gale, RP; Ho, WG; Winston, DJ, 1990) |
| "Two patients with acute leukemia developed Escherichia coli bacteremia while receiving oral ofloxacin for antibacterial prophylaxis during profound neutropenia." | 3.69 | Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. ( Andriof, E; Kern, WV; Markus, A, 1994) |
| "Ten patients with newly diagnosed haematological malignancy were given ofloxacin, 400 mg daily orally, for antibacterial prophylaxis during neutropenia." | 3.68 | Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy. ( Blundell, EL; Brown, NM; Chown, SR; MacGowan, AP; Reeves, DS; Slade, RR; White, LO, 1993) |
| "Levofloxacin reduced the bacterial infections and delays the onset of fever in chemotherapy-induced neutropenia especially in short duration (< 7 days)." | 2.74 | Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. ( Khan, MA; Rahman, MM, 2009) |
| "We performed population pharmacokinetic analysis for seven patients receiving LVFX as prophylaxis (200 mg, b." | 2.73 | Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. ( Fujimoto, Y; Kanbayashi, Y; Matsumoto, Y; Morimoto, Y; Nomura, K; Taniwaki, M, 2008) |
| "Ciprofloxacin was therefore superior to the other two fluoroquinolones in preventing infections due to Gram-negative bacteria in this population of neutropenic patients." | 2.67 | Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. ( Accorsi, P; Betti, S; D'Antonio, D; Dell'Isola, M; Favalli, C; Fioritoni, G; Iacone, A; Parruti, G; Piccolomini, R; Quaglietta, AM, 1994) |
| "Patients who are treated for acute leukemia should be offered prophylaxis with ciprofloxacin or levofloxacin." | 2.43 | Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. ( Bucaneve, G; Cullen, M; Fraser, A; Gafter-Gvili, A; Kern, WV; Leibovici, L; Paul, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (55.56) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Terashi, K | 1 |
| Oka, M | 1 |
| Soda, H | 1 |
| Fukuda, M | 1 |
| Kawabata, S | 1 |
| Nakatomi, K | 1 |
| Shiozawa, K | 1 |
| Nakamura, T | 2 |
| Tsukamoto, K | 1 |
| Noguchi, Y | 1 |
| Suenaga, M | 1 |
| Tei, C | 1 |
| Kohno, S | 1 |
| Esparza, EM | 1 |
| Takeshita, J | 1 |
| George, E | 1 |
| Rahman, MM | 1 |
| Khan, MA | 1 |
| Gracia Escudero, A | 1 |
| Martín González, M | 1 |
| Giménez Garrido, F | 1 |
| Clavero Farré, C | 1 |
| García Pérez, MJ | 1 |
| Alvarez Corral, G | 1 |
| Reyes Bertos, A | 1 |
| Villegas Maldonado, G | 1 |
| Rodríguez Cuartero, A | 1 |
| Reuter, S | 1 |
| Kern, WV | 5 |
| Sigge, A | 1 |
| Döhner, H | 1 |
| Marre, R | 3 |
| Kern, P | 3 |
| von Baum, H | 1 |
| Leibovici, L | 1 |
| Paul, M | 1 |
| Cullen, M | 1 |
| Bucaneve, G | 1 |
| Gafter-Gvili, A | 1 |
| Fraser, A | 1 |
| Borlenghi, E | 1 |
| Cattaneo, C | 1 |
| Capucci, MA | 1 |
| Pan, A | 1 |
| Quaresmini, G | 1 |
| Franco, F | 1 |
| Grazioli, L | 1 |
| Carosi, GP | 1 |
| Rossi, G | 1 |
| Nomura, K | 1 |
| Fujimoto, Y | 1 |
| Morimoto, Y | 1 |
| Kanbayashi, Y | 1 |
| Matsumoto, Y | 1 |
| Taniwaki, M | 1 |
| Markus, A | 1 |
| Andriof, E | 2 |
| Oethinger, M | 1 |
| Hacker, J | 1 |
| D'Antonio, D | 2 |
| Piccolomini, R | 1 |
| Iacone, A | 2 |
| Fioritoni, G | 2 |
| Parruti, G | 1 |
| Betti, S | 2 |
| Quaglietta, AM | 1 |
| Accorsi, P | 1 |
| Dell'Isola, M | 2 |
| Favalli, C | 1 |
| Hay, B | 1 |
| Arnold, R | 1 |
| Brown, NM | 1 |
| White, LO | 1 |
| Blundell, EL | 1 |
| Chown, SR | 1 |
| Slade, RR | 1 |
| MacGowan, AP | 1 |
| Reeves, DS | 1 |
| Spanik, S | 1 |
| Trupl, J | 1 |
| Kunova, A | 1 |
| Botek, R | 1 |
| Sorkovska, D | 1 |
| Grey, E | 1 |
| Studena, M | 1 |
| Lacka, J | 1 |
| Oravcova, E | 1 |
| Krchnakova, A | 1 |
| Rusnakova, V | 1 |
| Svec, J | 1 |
| Krupova, I | 1 |
| Grausova, S | 1 |
| Stopkova, K | 1 |
| Koren, P | 1 |
| Krcmery, V | 1 |
| Pizzigallo, E | 1 |
| Piergallini, A | 1 |
| Di Gianfilippo, R | 1 |
| Olioso, P | 1 |
| Torlontano, G | 1 |
| Tsutani, H | 1 |
| Imamura, S | 1 |
| Ueda, T | 1 |
| Yoshida, H | 1 |
| Iwasaki, H | 1 |
| Fukushima, T | 1 |
| Yoshimura, T | 1 |
| Toyooka, S | 1 |
| Sawada, H | 1 |
| Tashima, M | 1 |
| Okuma, M | 1 |
| Winston, DJ | 1 |
| Ho, WG | 1 |
| Bruckner, DA | 1 |
| Gale, RP | 1 |
| Champlin, RE | 1 |
1 review available for ofloxacin and Leukemia
| Article | Year |
|---|---|
Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
Topics: Acute Disease; Antibiotic Prophylaxis; Antineoplastic Agents; Bone Marrow Transplantation; Ciproflox | 2006 |
9 trials available for ofloxacin and Leukemia
| Article | Year |
|---|---|
Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacteria | 2009 |
[A prospective, controlled, non-randomized study of three cohorts to test the effectiveness of two antibiotics levofloxacin and cotrimoxazol on antibacterial prophylaxis in neutropenic patients].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Humans; Leukemia; Levofloxac | 2003 |
Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Topics: Amyloidosis; Anemia, Aplastic; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; | 2005 |
Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Dose-Response Relationship, Drug; Female | 2008 |
Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
Topics: Adult; Aged; Agranulocytosis; Anti-Infective Agents; Bacteremia; Bacterial Infections; Ciprofloxacin | 1994 |
A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bone Marrow Transplantation; Cyclospo | 1994 |
Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents; Bacterial Infections; Female; Human | 1992 |
Use of ofloxacin in prevention and treatment of secondary infections in hematological malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Female; Humans; Leukemia; Lymphoma; Male | 1991 |
Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacteria; Bacterial Infections; Digestive System; Drug The | 1990 |
8 other studies available for ofloxacin and Leukemia
| Article | Year |
|---|---|
Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Int | 2000 |
Lymphomatoid hypersensitivity reaction to levofloxacin during autologous stem cell transplantation: a potential diagnostic pitfall in patients treated for lymphoma or leukemia.
Topics: Anti-Bacterial Agents; Biomarkers, Tumor; Diagnosis, Differential; Drug Eruptions; Female; Hematopoi | 2011 |
Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates.
Topics: Acute Disease; Adult; Aged; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Ciprofloxac | 2007 |
Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Infective Agents; Bacteremia; Drug Resistance, Micr | 1994 |
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.
Topics: Anti-Infective Agents; Cancer Care Facilities; Cross Infection; Drug Resistance, Microbial; Drug Uti | 1994 |
Absorption of oral ofloxacin after cytotoxic chemotherapy for haematological malignancy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Intest | 1993 |
Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis.
Topics: Acute Disease; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Dru | 1997 |
Occurrence of bacteremia in hematologic patients.
Topics: Adolescent; Adult; Aged; Bacteremia; Bone Marrow Transplantation; Catheterization; Ciprofloxacin; Fe | 1992 |